The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 306.00
Bid: 308.00
Ask: 308.50
Change: 14.50 (4.97%)
Spread: 0.50 (0.162%)
Open: 298.00
High: 308.00
Low: 285.50
Prev. Close: 291.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

11 Jul 2014 07:00

RNS Number : 0240M
Synthomer PLC
11 July 2014
 



11th July 2014

 

Synthomer plc

 

Trading update

 

Synthomer plc ("Synthomer" or the "Group") today issues a trading update ahead of its interim results on 11th August 2014.

 

The Group has continued to see similar trends to those seen during the first quarter of the year which it highlighted at the time of its Interim Management Statement on 1 May 2014.

 

In Europe and North America, trading has continued in line with the first quarter of the year and our expectations. Volumes were ahead of the prior year in our Construction & Coatings, Functional Polymers and Performance Polymers segments, whilst average cash margins in the second quarter have remained similar to the first three months of 2014.

 

In Asia and Rest of the World, the strong competition between glove manufacturers that we reported at the time of our Q1 IMS in May has continued. This has caused ongoing margin pressure in our Nitrile business, exacerbated by weak Butadiene pricing and a related period of customer de-stocking. This prolonged pressure means that operating profit for the first half of the year for Asia will be approximately £4m below our first half performance in 2013 (H1 2013: £11.5m). However, as the second half progresses we continue to expect demand for nitrile latex to grow and unit margins to firm.

 

In addition, sterling strengthened further during the period. As a result, we now expect currency translation to have an adverse impact on full year operating profit of approximately £5m, an increase of £1m over our original expectations, assuming no further change to current rates.

 

The result of weaker margins in our nitrile business and adverse currency translation means that we now expect full year profit before tax to be broadly in-line with the level achieved in 2013.

Enquiries:

 

Adrian Whitfield, Chief Executive OfficerDavid Blackwood, Chief Financial Officer

Tel: 01279 436 211

Pendomer Communications

Charles Armitstead / Rosie Oddy

Tel: 020 3603 5220

 

The company will host a conference call for analysts at 8.00am (BST) today:

 

Dial-In: +44 203 427 0662.

Please quote "Synthomer" to gain access to the call.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDMGMNKGKGDZM
Date   Source Headline
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding
30th Jul 201912:59 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:55 pmRNSDirector/PDMR Shareholding
30th Jul 201912:54 pmRNSDirector/PDMR Shareholding
30th Jul 201912:53 pmRNSDirector/PDMR Shareholding
30th Jul 201912:52 pmRNSDirector/PDMR Shareholding
30th Jul 201912:51 pmRNSDirector/PDMR Shareholding
30th Jul 201912:50 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201911:31 amRNSResults of Rump Placing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.